Cash Flow Statement

Amortization of Deferred Charges Amortization of Deferred Charges Amortizatization of Intangibles Amortizatization of Intangibles Asset Writedowns and Impairment Asset Writedowns and Impairment Capital Expenditures Capital Expenditures Cash from Financing Activities Cash from Financing Activities Cash from Investing Activities Cash from Investing Activities Cash from Operations Cash from Operations Change in Account Payables Change in Account Payables Change in Accured Expenses Change in Accured Expenses Change in Acquisitions & Divestments Change in Acquisitions & Divestments Change in Cash Change in Receivables Change in Receivables Depreciation & Amortization (CF)Depreciation & Amortization (CF)Depreciation and Depletion Depreciation and Depletion Free Cash Flow Free Cash Flow Gains from Investment Securities Gains from Investment Securities Gains from Sales and Divestitures Gains from Sales and Divestitures Long-Term Debt Repayments Net Cash Flow Net Cash Flow Net Income Non-cash Items Non-cash Items Other Working Capital Changes Other Working Capital Changes Preferred Shares Issued Sales of Property, Plant and Equipment Sales of Property, Plant and Equipment Share-based Compensation Share-based Compensation Shares Issued Short-Term Debt repayments

Daily Values

Growth Metrics

Others

Accumulated Depreciation & Amortization Accumulated Depreciation & Amortization EBIAT Leases Long-Term Debt Repayments Machine, Furnitures, Fixtures & Other Other Gross PP&E Adjustments Other Gross PP&E Adjustments Preferred Shares Issued Property, Plant & Equipment (Gross)Property, Plant & Equipment (Gross)Receivables - Net Receivables - Other Shares Issued Shares Outstanding Shares Outstanding Short-Term Debt repayments

Corbus Pharmaceuticals Holdings (CRBP) Shares Issued (2016 - 2025)

Corbus Pharmaceuticals Holdings has reported Shares Issued over the past 7 years, most recently at -$74000.0 for Q4 2023.

For Q4 2023, Shares Issued changed N/A year-over-year to -$74000.0; the TTM value through Dec 2023 reached $77056.0, changed N/A, while the annual FY2024 figure was $182.1 million, 343405.66% up from the prior year.
Shares Issued for Q4 2023 was -$74000.0 at Corbus Pharmaceuticals Holdings, down from $7000.0 in the prior quarter.
Over five years, Shares Issued peaked at $62.5 million in Q1 2021 and troughed at -$99.1 million in Q4 2020.
A 4-year average of $5.9 million and a median of $102708.0 in 2019 define the central range for Shares Issued.
On a YoY basis, Shares Issued climbed as much as 14508.38% in 2020 and fell as far as 9909758800.0% in 2020.
Year by year, Shares Issued stood at -$1.0 in 2019, then crashed by 9909758800.0% to -$99.1 million in 2020, then skyrocketed by 163.11% to $62.5 million in 2021, then tumbled by 100.12% to -$74000.0 in 2023.
Business Quant data shows Shares Issued for CRBP at -$74000.0 in Q4 2023, $7000.0 in Q3 2023, and $107000.0 in Q2 2023.